2020
Consolidation Therapy in Primary Central Nervous System Lymphoma
Kim P, Omuro A. Consolidation Therapy in Primary Central Nervous System Lymphoma. Current Treatment Options In Oncology 2020, 21: 74. PMID: 32725379, DOI: 10.1007/s11864-020-00758-4.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyCentral nervous system lymphomaLong-term remissionNervous system lymphomaConsolidation therapyInduction therapyPerformance statusTransplant candidatesSystem lymphomaOpinion statementPrimary central nervous system lymphomaPrimary central nervous system lymphomaAutologous stem cell transplantTransplant-related mortality riskAdequate organ functionFavorable performance statusInitial induction therapyECOG performance statusHigh-dose cytarabineHigh-dose methotrexateHigh-dose chemotherapyStem cell transplantEnd of inductionHigh response rateCurative intentMyeloablative regimen
2013
A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors.
Sandler A, Taylor M, Urba W, Omuro A, Anderson B, Hansen D, Fisher B, Claeys A, Greathouse A, McLean S, Karmali R. A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors. Journal Of Clinical Oncology 2013, 31: 2518-2518. DOI: 10.1200/jco.2013.31.15_suppl.2518.Peer-Reviewed Original ResearchAdvanced solid tumorsCell lung cancerStable diseaseLung cancerSolid tumorsSquamous cell lung cancerSmall cell lung cancerAdequate organ functionGrade 3 fatigueCreatine kinase elevationSquamous cell carcinomaColon tumor xenograftsAnti-tumor effectsAnti-invasive propertiesPharmacokinetic samplingAdverse eventsQTc prolongationCell carcinomaTumor responseEGFR mutationsPIK3CA mutationsMalignant gliomasLung adenocarcinomaTumor assessmentCT scan
2007
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases
Iwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT, Abrey LE. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. Journal Of Neuro-Oncology 2007, 87: 85-90. PMID: 17987262, DOI: 10.1007/s11060-007-9491-3.Peer-Reviewed Original ResearchConceptsKarnofsky Performance ScaleProgressive brain metastasesPhase II trialBrain metastasesII trialResponse rateMedian Karnofsky performance scaleWhole-brain radiation therapyAdequate organ functionBrain metastasis resectionObjective radiographic responseRadiographic response rateSingle-agent temozolomideGrade 3/4 toxicitiesRecurrent brain metastasesPopulation of patientsPrimary tumor siteYears of agePrior therapyStable diseaseVinorelbine 25Metastasis resectionPrimary endpointMethods PatientsOverall survivalA phase II trial of temozolomide and vinorelbine for patients with recurrent brain metastases
Iwamoto F, Omuro A, Raizer J, Nolan C, Hormigo A, Lassman A, Gavrilovic I, Abrey L. A phase II trial of temozolomide and vinorelbine for patients with recurrent brain metastases. Journal Of Clinical Oncology 2007, 25: 2050-2050. DOI: 10.1200/jco.2007.25.18_suppl.2050.Peer-Reviewed Original ResearchPhase II trialRecurrent brain metastasesObjective radiographic responseBrain metastasesII trialRadiographic responseResponse rateWhole-brain radiation therapyAdequate organ functionBrain metastasis resectionSingle-agent temozolomideGrade 3/4 toxicitiesPhase I trialPhase II componentPopulation of patientsFavorable toxicity profileBlood-brain barrierPrimary tumor siteHead/neckTwo-stage clinical trialAssessable patientsMedian KPSMedian PFSPrior therapyMetastasis resection